TIMI Risk Score for UA/NSTEMI

Use the TIMI risk score (0–7) for unstable angina and NSTEMI: seven presentation criteria, risk bands, bedside interpretation, monitoring and invasive strategy context—educational overview.

TIMI Risk Score for UA / NSTEMI

Seven binary criteria (0–7 points). Intended for patients with unstable angina or NSTEMI. Each checked item adds one point.

Age ≥ 65 years1 point if present.

≥ 3 risk factors for CADFamily history of CAD, hypertension, hyperlipidemia, diabetes mellitus, or current tobacco use.

Known CAD (stenosis ≥ 50%)Prior angiography, stress test, or other objective documentation.

Aspirin use in the prior 7 daysAny dose for any indication.

≥ 2 episodes of severe angina in the last 24 hoursSevere ischemic symptoms by clinical assessment.

ST-segment deviation ≥ 0.5 mmTransient or persistent ST depression or elevation on ECG (not necessarily persistent).

Elevated cardiac biomarkerse.g., troponin or CK-MB above the assay’s URL for MI.

Disclaimer: For education only. Use only in appropriate clinical contexts by qualified professionals; this tool does not replace full assessment, serial ECGs/biomarkers, or institutional pathways.

TIMI Risk Score for UA/NSTEMI — Scoring Guide

Overview

The TIMI risk score for unstable angina and non–ST-elevation myocardial infarction (UA/NSTEMI) assigns one point for each of seven historical, clinical, ECG, and laboratory features present at presentation. The sum ranges from 0 to 7 and correlates with the short-term incidence of death, recurrent MI, or urgent revascularization.

Criteria (1 point each)

Age ≥ 65 years
≥ 3 coronary artery disease risk factors (e.g., family history, hypertension, hyperlipidemia, diabetes, current smoking)
Known coronary artery disease with ≥ 50% stenosis on prior angiography or positive functional study
Aspirin use in the preceding 7 days
≥ 2 anginal episodes in the prior 24 hours
ST-segment deviation ≥ 0.5 mm on presenting ECG
Elevated serum cardiac markers (troponin or CK-MB)

14-day event rates (TIMI 11B)

Approximate rates for the composite of death, MI, or urgent revascularization:

Score	Approximate risk
0–1	~5%
2	~8%
3	~13%
4	~20%
5	~26%
6–7	~41%

Clinical use

The score supports risk stratification alongside clinical judgment, serial troponins, ECGs, and imaging or invasive strategies as indicated. It should not be used for STEMI or as the sole determinant of therapy.

Reference

Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non–ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000;284(7):835–842.

Understanding the TIMI risk score in UA and NSTEMI

The Thrombolysis in Myocardial Infarction (TIMI) risk score for unstable angina (UA) and non–ST-elevation myocardial infarction (NSTEMI) is one of the most widely taught clinical tools for early risk stratification in acute coronary syndrome (ACS) without persistent ST-segment elevation. It was designed to summarize, at presentation, a small set of historical, clinical, electrocardiographic, and laboratory findings that independently associate with adverse cardiac events over the subsequent days to weeks.

Unlike scores that require continuous variables or nomograms, the UA/NSTEMI TIMI score is intentionally simple: each of seven prespecified criteria is worth one point, and the total ranges from 0 to 7. That simplicity supports rapid use in emergency departments, chest pain units, and inpatient cardiology settings, where decisions about monitoring intensity, antithrombotic intensity, timing of invasive evaluation, and patient counseling must often be made under time pressure.

Clinical context: why stratify UA and NSTEMI?

UA and NSTEMI represent a spectrum of acute myocardial ischemia caused by coronary plaque instability, thrombus formation, and supply–demand mismatch. Some patients follow a relatively benign course with medical therapy and planned evaluation; others progress to recurrent ischemia, larger infarction, arrhythmia, or hemodynamic compromise. Biomarkers (especially high-sensitivity troponin) and electrocardiographic changes improve diagnostic precision, but prognosis is not determined by a single test—it reflects the interplay of age, comorbidity, prior coronary disease, aspirin exposure, symptom burden, ischemic ECG patterns, and marker positivity.

Risk scores do not replace clinical judgment, serial assessments, or institutional pathways. Their value is to structure bedside reasoning, improve communication among providers, and align monitoring and escalation plans with estimated event risk.

What the score estimates

In its original derivation cohort, the score correlates with the short-term incidence of a composite that includes death, recurrent myocardial infarction, and need for urgent revascularization (reflecting severe or refractory ischemia). When you interpret the numeric total, think of it as a probability gradient, not a binary rule: low scores are associated with lower observed event frequencies, while high scores identify patients in whom aggressive antithrombotic therapy, intensive monitoring, and early invasive strategies are more often considered.

Exact event rates vary by era (contemporary high-sensitivity troponin assays, earlier invasive approaches, and refined medical therapy have changed absolute risks compared with older trial populations). The score remains useful as a relative stratification tool anchored to the original published outcome relationships.

How to calculate the score

Work through the seven items at initial presentation (or the earliest time point when all data are available). Each item is binary: if present, add 1 point. If absent, add 0. Sum the points.

Age ≥ 65 years — One point if the patient has reached or passed this threshold at presentation.
≥ 3 coronary artery disease (CAD) risk factors — One point if at least three of the following are present: family history of premature CAD, treated or untreated hypertension, hypercholesterolemia (or known dyslipidemia), diabetes mellitus, or current tobacco use. The intent is to capture atherosclerotic burden and systemic risk beyond the acute event.
Known CAD with ≥ 50% stenosis — One point if prior coronary angiography, prior revascularization, or a prior positive functional or imaging study documents hemodynamically significant epicardial disease. This item flags patients who already have substrate for recurrent ischemia and may behave differently from first-presentation ACS.
Aspirin use in the prior 7 days — One point if the patient took aspirin during the week before presentation (any dose or schedule used clinically at the time of derivation). This variable proxies for ongoing platelet activation despite antiplatelet therapy, which identifies a higher-risk biology in many datasets.
≥ 2 episodes of severe angina in the last 24 hours — One point if the history documents repeated, clinically significant ischemic pain episodes within the prior day. This reflects symptom intensity and instability rather than a single brief complaint.
ST-segment deviation ≥ 0.5 mm — One point if the presenting ECG demonstrates at least 0.5 mm of ST depression or transient ST elevation in contiguous leads (criteria as applied in the original studies). This captures ongoing electrical evidence of ischemia beyond nonspecific T-wave changes alone.
Elevated cardiac biomarkers — One point if serum markers of myocardial injury (for example troponin or CK-MB, depending on the assay era) are above the relevant diagnostic threshold for infarction in your laboratory and clinical context. In modern practice this most often means a positive troponin consistent with myocardial injury/NSTEMI rather than unstable angina without biomarker rise.

Interpreting the total score

After summing points, map the total to a qualitative risk band and to approximate short-term event frequencies from the classic TIMI 11B–based reporting:

Score range	Risk band (qualitative)	Approximate 14-day composite event risk*
0–2	Lower	Low single digits to roughly 8% depending on exact score
3–4	Intermediate	Approximately mid-teens to low twenties percent
5–7	Higher	Substantially elevated; highest scores approach very high event rates in historical cohorts

*Composite typically includes death, recurrent MI, or urgent revascularization for severe ischemia; absolute percentages shift with contemporary care patterns.

Clinicians often use the score alongside other tools (for example GRACE) and alongside dynamic changes in troponin kinetics, recurrent ECG shifts, rhythm instability, renal function, hemoglobin, heart failure signs, and bleeding risk. A “low” score does not eliminate ACS risk; a “high” score does not mandate a single treatment path without considering contraindications and patient goals.

Practical application at the bedside

Documentation and handoffs. Stating “TIMI UA/NSTEMI score = X” in the record helps receiving teams understand the initial risk snapshot, especially when patients move from the ED to a telemetry floor or catheterization laboratory holding area.

Monitoring intensity. Higher scores justify closer nursing observation, continuous telemetry when indicated, readiness for repeat ECGs with symptoms, and protocols for serial troponin measurement aligned with institutional guidelines.

Invasive strategy timing. Many pathways use risk scores as one input when deciding between routine early angiography versus a more selective approach. The score should be integrated with symptoms, ischemic burden, shock, arrhythmia, and comorbidity rather than used in isolation.

Antithrombotic and antiplatelet decisions. Higher-risk profiles often prompt consideration of more intensive P2Y₁₂ inhibitor strategies or parenteral anticoagulation where appropriate, balanced against bleeding risk scores and renal function.

Patient communication. Explaining that several independent risk features are present can help patients understand why admission, repeat blood tests, or coronary angiography is recommended, without implying deterministic prediction.

Common pitfalls and limitations

STEMI exclusion. This score is not intended for patients with persistent ST-elevation MI; STEMI care follows reperfusion-focused pathways.
Biomarker timing. Early presentation before troponin release may underestimate injury; repeat testing remains essential even if the first score seems “low.”
ECG subtleties. Nondiagnostic ECGs do not rule out ACS; ST criteria must be applied carefully with clinical correlation.
Renal disease and comorbidity. The seven variables do not explicitly encode renal failure, anemia, frailty, or infection—conditions that modify prognosis and therapeutic options.
Contemporary practice drift. Invasive management and pharmacology have evolved; interpret absolute risk estimates as historical anchors, not precise individualized forecasts.

Educational notice: This article supports learning and shared decision-making. It does not establish a standard of care, replace specialist consultation, or supersede local protocols, contraindications, or institutional order sets.